Skip to main content

Table 2 Univariable association between patient characteristics and risk of severe (grade 3 or 4) rash for patients using vemurafenib alone or in combination with cobimetinib for advanced melanoma

From: Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

 Events/Patients (%)OR95% CIP-value
Sex   < 0.001
 Male64/565 (11%)1.00  
 Female86/397 (22%)2.171.52 to 3.09 
Age (years)   0.462
  < 5046/345 (13%)1.00  
 50 to 5942/253 (17%)1.310.83 to 2.07 
 60 to 6939/219 (18%)1.420.89 to 2.27 
  ≥ 7023/145 (16%)1.240.72 to 2.15 
ECOG PS   0.597
 0102/639 (16%)1.00  
 1+47/317 (15%)0.900.61 to 1.32 
Weight (kg)   0.002
  < 6652/233 (22%)1.00  
 66–7838/242 (16%)0.640.40 to 1.02 
 79–9023/247 (9%)0.360.21 to 0.62 
  ≥ 9136/233 (15%)0.630.39 to 1.01 
Body mass index (kg/m2)   0.385
 18.5–25.064/345 (19%)1.00  
  < 18.53/21 (14%)0.740.21 to 2.59 
 25.1–29.947/340 (14%)0.710.47 to 1.08 
  ≥ 30.033/226 (15%)0.750.47 to 1.18 
eGFR (ml/min/1.73 m2)   0.228
  > 9071/517 (14%)1.00  
 60–8967/388 (17%)1.300.91 to 1.88 
 45–598/41 (20%)1.460.64 to 3.30 
 30–444/13 (31%)2.810.84 to 9.38 
Bilirubin   0.225
  ≤ ULN146/913 (16%)1.00  
  > ULN3/36 (8%)0.480.14 to 1.58 
AST   0.901
  ≤ ULN132/843 (16%)1.00  
  > ULN16/103 (16%)0.960.55 to 1.70 
ALT   0.108
  ≤ ULN138/843 (16%)1.00  
  > ULN11/106 (10%)0.580.30 to 1.12 
History of atopy   0.279
 No125/767 (16%)1.00  
 Yes22/176 (13%)0.770.48 to 1.24 
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, eGFR Estimated glomerular filtration rate, OR odds ratio, ULN upper limit of normal